SCHEMBL20577943

SCHEMBL20577943

CC(C)(C)OC(=O)Nc1ccc(F)c(NC(=O)c2cc(C(F)(F)F)ccn2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.47
BRAF P15056 8/20 0.46
GRM4 Q14833 2/20 0.44
RAF1 P04049 5/20 0.43
PYGL P06737 1/20 0.43
PYGM P11217 1/20 0.43
DDR1 Q08345 1/20 0.43
ANO1 Q5XXA6 1/20 0.43
MAPK13 O15264 2/20 0.42
KDR P35968 2/20 0.42
MAPK14 Q16539 2/20 0.42
PLK4 O00444 1/20 0.42
AURKA O14965 1/20 0.42
JAK2 O60674 1/20 0.42
MAP4K4 O95819 1/20 0.42
ABL1 P00519 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
LYN P07948 1/20 0.42
RET P07949 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28664640 0.84 RXFP1 (0.45) RXFP1BRAFKDRSYKHIPK4
SCHEMBL29448791 0.83 RXFP1 (0.55) RXFP1KDRRETTMPRSS4
SCHEMBL20577956 0.81 RXFP1 (0.48) RXFP1BRAFRAF1KDR
SCHEMBL20578021 0.81 LMNA (0.46) BRAFRAF1
SCHEMBL20577759 0.80 RXFP1 (0.44) RXFP1BRAFGRM4RAF1KDR
SCHEMBL20578150 0.80 RXFP1 (0.53) RXFP1TMPRSS4
SCHEMBL20577777 0.80 RXFP1 (0.53) RXFP1KDRTMPRSS4
SCHEMBL20578183 0.80 ACLY (0.47) RXFP1DDR1KDRTMPRSS4
SCHEMBL20577989 0.79 CBLB (0.50) RXFP1GRM4
SCHEMBL20577987 0.79 BRAF (0.47) RXFP1BRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3412670-B1 PYRIDINE DERIVATIVES INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE THEREOF SAMJIN PHARM CO LTD (KR) 2022-03-09 EP disclosed
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2020-11-24 US disclosed
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2019-10-03 US disclosed
EP-3412670-A1 PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2018-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof BRAF, KDR, RAF1 RXFP1 186/4885BRAF 1/4885GRM4 4218/4885
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof BRAF, KDR, RAF1 RXFP1 186/4885BRAF 1/4885GRM4 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.